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Primary Sjo¨gren’s syndrome is a multisystem autoimmune disease characterized by hypo-
function of salivary and lacrimal glands and possible multi-organ system manifestations.
Over the past 15 years, three sets of diagnostic criteria have been proposed, but none has
included salivary gland ultrasonography. However, recent studies support its role in the
diagnosis and prognostic evaluation of patients with Sjo¨gren’s syndrome. This study aimed
to determine the value of salivary gland ultrasonography in the diagnosis and prognosis of
Sjo¨gren’s syndrome by relating ultrasonography severity scores to clinical and laboratory
data.
Methods
Seventy patients who fulfilled the 2002 American-European Consensus Group diagnostic
criteria for primary Sjo¨gren’s syndrome were selected from 84 patients receiving care in spe-
cialized outpatient clinics at our institution from November 2013 to May 2016. Their serol-
ogy, European League Against Rheumatism Sjo¨gren’s syndrome disease activity index
(ESSDAI), salivary flow rate, immunoglobulin G, and salivary and serum beta-2 microglobu-
lin levels were measured. Salivary gland ultrasonography was performed by an experienced
radiologist, using scores of 1–4 to classify salivary gland impairment.
Results
Salivary gland ultrasonography scores of 1 or 2 were associated with an ESSDAI < 5. Ultra-
sonography scores of 3 or 4 were associated with an ESSDAI5 (p = 0.064), a positive anti-
nuclear antibody test (p = 0.006), positive anti-Ro/SSA antibodies (p = 0.003), positive anti-
La/SSB antibodies (p = 0.077), positive rheumatoid factor (p = 0.034), and immunoglobulin
G levels > 1600 mg/dL (p = 0.077). Salivary flow rate was lower in patients with scores 3 or 4
(p = 0.001).
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Conclusion
This study provides further evidence that salivary gland ultrasonography can be used not
only for diagnosis but also for prognostic evaluation of primary Sjo¨gren’s syndrome. These
findings confirm what has been reported in the literature. However, further analyses involv-
ing larger matched samples are required to support this finding and include salivary gland
ultrasonography as part of the diagnostic criteria for Sjo¨gren’s syndrome.
Introduction
Primary Sjo¨gren’s syndrome (pSS) is a systemic autoimmune disease clinically characterized by
oral and ocular dryness, reflecting lymphocytic infiltration and subsequent exocrine gland dys-
function. However, during disease progression, any organ or mucosal surface may be involved.
Thus, pSS presents as a heterogeneous non-organ-specific autoimmune entity, encompassing a
wide spectrum of clinical manifestations, serological abnormalities, and scattered complications
[1]. The incidence rate of pSS is estimated at about 6.92 per 100,000 person-years, with a
female-to-male ratio in incidence data of 9:1 [2]. Prevalence rates vary widely between studies,
but they are estimated at about 43.03 cases per 100,000 inhabitants when considering only pop-
ulation-based studies [2]. The peak incidence of pSS is in women aged 55–65 years [2].
Because pSS is a systemic autoimmune disorder, several autoantibodies are detected in pSS
patients [3], of which antinuclear antibodies (ANA) are the most frequently detected (in up to
80% of patients); however, the most relevant autoantibodies are directed against Ro/SSA or
La/SSB antigens [3]. According to the 2002 American-European Consensus Group (AECG)
classification criteria [4], the diagnosis is based on the report of dry mouth and dry eyes by
patients, salivary gland biopsy, sialography and/or scintigraphy, positive serology, and ophthal-
mic testing to confirm tear deficiency. The 2002 AECG criteria have specificity of 95.2% and
sensitivity of 89.5% [4].
In 2012 and 2016, two sets of diagnostic criteria were proposed [5, 6]. However, salivary
gland ultrasonography (SGUS) was not included in any set of diagnostic criteria even though
some studies have indicated that it could replace scintigraphy, sialography and other imaging
techniques in the diagnosis of pSS [7–11]. SGUS is simple, noninvasive, widely available, non-
irradiating and less expensive than other imaging techniques [12]. Its use allows us to classify
the echogenicity, homogeneity, degeneration, fibrosis and calcification of the glandular
parenchyma.
In 1992, De Vita et al. [13] comparatively investigated SGUS abnormalities in patients with
either primary or secondary Sjo¨gren’s syndrome and controls. Scores of 0–3 were assigned to
each pair of glands according to inhomogeneity, hypoechogenicity, size, and posterior borders
of the parotid and submandibular glands, and this scoring system showed a sensitivity of
88.8% and a specificity of 84.6% for pSS [13]. Since then, there have been an increasing num-
ber of studies evaluating ultrasonography in the diagnosis of pSS. Hocevar et al. [14] evaluated
new parameters in glandular tissue and suggested scores of 0–48 according to inhomogeneity,
echogenicity, number of hypoechoic areas, and gland borders, achieving a sensitivity of 58.8%
and a specificity of 98.7%. In a prospective cohort of patients with pSS, Cornec et al. [12] exam-
ined submandibular and parotid glands bilaterally and the findings were graded on a scale of
0–4, where grade 0 = normal, grade 1 = small hypoechogenic areas without echogenic bands,
grade 2 = multiple hypoechogenic areas measuring < 2 mm with echogenic bands, grade
3 = multiple hypoechogenic areas measuring 2–6 mm with hyperechogenic bands, and grade
4 = multiple hypoechogenic areas measuring > 6 mm or multiple calcifications with echogenic
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bands. This scoring system achieved 62.8% sensitivity and 95.0% specificity [12]. In addition, a
large number of studies have produced convincing data supporting the usefulness of SGUS for
the prognostic stratification of patients with pSS, showing that patients with pathologic SGUS
have positive serology, higher disease activity, and significantly more often several risk factors
for lymphoma than patients with normal SGUS findings [15, 16].
New indices have been developed to objectively assess systemic and symptomatic manifes-
tations in patients with pSS. The European League Against Rheumatism (EULAR) Sjo¨gren’s
syndrome disease activity index (ESSDAI) was developed in 2009 by consensus of a large
group of worldwide experts from European and North American countries [17]. The ESSDAI
includes 12 organ-specific domains (cutaneous, pulmonary, renal, articular, muscular, periph-
eral nervous system, central nervous system, hematological, glandular, constitutional, biologi-
cal, and lymphadenopathy), and scores< 5 indicate low activity, scores5 and13 indicate
moderate activity, and scores14 indicate high activity [18].
The objective of the present study was to determine whether the severity of salivary gland
involvement as assessed morphologically by SGUS or functionally by salivary flow could pre-
dict higher ESSDAI in patients with pSS.
Materials and methods
Participants
Seventy patients with pSS were selected from a cohort of 84 patients followed in the Depart-
ments of Internal Medicine and Ophthalmology at Universidade Federal de São Paulo from
November 2013 to May 2016. The 2002 AECG criteria were used to select patients for inclu-
sion. Exclusion criteria were hepatitis B or C, sarcoidosis, other connective tissue diseases, and
current biological therapy. The following data were collected from each participant: previous
medical history; complaints related to oral and ocular dryness; eye examination (ocular stain-
ing score and Schirmer’s test); serological tests including rheumatoid factor (nephelometry),
ANA (indirect immunofluorescence), anti-Ro/SSA and anti-La/SSB (radial double immuno-
diffusion), and immunoglobulin G (IgG) levels (nephelometry); stimulated salivary flow rate;
erythrocyte indices; urinalysis; and bilateral SGUS of the parotid and submandibular glands.
All included patients fulfilled the AECG classification criteria [4] and gave written informed
consent to participate. The study was approved by the local ethics committee at Universidade
Federal de São Paulo (CAAE 17092013.8.0000.5505).
Ultrasonographic examination
SGUS was performed by the same investigator, an experienced radiologist, using a real-time
scanner (Logiq P6; GE Healthcare, Waukesha, WI, USA) with a 12-MHz linear array trans-
ducer. Both the parotid and submandibular glands were scanned and echostructure of each
gland was graded on a scale of 1 to 4. According to this scale, grade 1 = small hypoechogenic
areas without echogenic bands, grade 2 = multiple hypoechogenic areas measuring < 2 mm
with echogenic bands, grade 3 = multiple hypoechogenic areas measuring 2–6 mm with hyper-
echogenic bands, and grade 4 = multiple hypoechogenic areas measuring > 6 mm or multiple
calcifications with echogenic bands [12]. Each patient received one score per gland and the
highest score obtained was considered in the analysis.
Salivary flow
The participants were asked to spit saliva into a graduated test tube for 15 minutes after saliva-
tion was stimulated with 2% citric acid applied to the lateral borders of the tongue. Stimulation
Salivary gland ultrasonography importance for Sjo¨gren’s syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0182287 August 4, 2017 3 / 10
with 2% citric acid followed the protocol described by Navazesh et al. [19]. This procedure was
performed at the same time in the morning at normal room temperature and humidity and
participants were asked not to eat/drink/smoke for at least 2 hours beforehand. The entire
saliva sample was stored at −20˚C and salivary and serum beta-2 microglobulin (β2M) levels
were measured using an Abcam β2M ELISA kit.
ESSDAI determination
The date of disease diagnosis was defined as the date of fulfillment of the 2002 AECG criteria
as confirmed by the physician in charge of the patients in the cohort. Systemic involvement
was defined according to the ESSDAI, which evaluates the following 12 domains or organ sys-
tems: constitutional, cutaneous, articular, muscular, lymphadenopathy, glandular, pulmonary,
central nervous system, peripheral nervous system, hematological, renal, and biological [17].
Statistical analysis
For analysis purposes, participants were divided into two groups according to SGUS score:
score of 1 or 2 and score of 3 or 4. Descriptive statistics (mean, SD and 95% confidence interval
[95%CI] for continuous variables and frequency and percentage for categorical variables) were
used to characterize the patients in the two groups. Continuous variables were compared using
Student’s t test (for variables with normal distribution) or the Mann-Whitney test (for vari-
ables with skewed distribution) and categorical variables were assessed using the chi-square
test. Data analysis was performed using SPSS, version 19.0, and the level of statistical signifi-
cance was set at 5%.
Results
The sample consisted of 70 patients, 68 (97%) women and 2 (3%) men, with a mean (SD) age
of 55.74 (11.89) years and median disease duration of 6.0 years (range, 2.0–10.0 years). The
most common symptom was dryness of the mouth and/or eyes (100%).
The main serological features at diagnosis were ANA1/80 in 58/70 (83%) patients, anti-
Ro/SSA in 39/70 (58%), anti-La/SSB in 22/70 (31%), and rheumatoid factor in 38/60 (54%).
The ESSDAI was 0–4 in 51/70 (72.9%), 5–14 in 18/70 (26%), and15 in 1/70 (1%). An ESS-
DAI< 5 was found in 51 patients (72.9%), while an ESSDAI5 was found in 19 patients
(27.1%). Table 1 shows the characteristics of the study sample divided into two groups accord-
ing to SGUS findings.
In order to relate SGUS findings to clinical and laboratory variables, patients were divided
into two groups: SGUS score of 1 or 2 (n = 23, 33%) and SGUS score of 3 or 4 (n = 47, 67%).
The group with scores 3 or 4 had proportionally more patients with an ESSDAI5 (p = 0.064),
with positive ANA (p = 0.006), and with positive rheumatoid factor (p = 0.034) than the group
with scores 1 or 2. There was also an association between patients with SGUS scores of 3 or 4
and presence of anti-Ro/SSA (p = 0.003), but not of anti-La/SSB (Table 1).
Disease duration and age did not relate to the ESSDAI or SGUS score. There was no signifi-
cant difference in the proportion of IgG > 1600 mg/dL between the two groups. However, a
tendency to higher IgG levels was observed in the group with scores 3 or 4 than in the group
with scores 1 or 2 (p<0.100). IgG levels did not relate to the ESSDAI. Patients with positive
anti-Ro/SSA had proportionally more IgG > 1600 mg/dL (p = 0.014), but the same was not
true for anti-La/SSB.
The relationship between salivary flow and SGUS score was significant, with patients with
scores of 1 or 2 showing significantly higher salivary flow than patients with scores of 3 or 4
(p = 0.001). Salivary β2M levels did not relate to any variable (Table 1).
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Discussion
In the present study, we evaluated the prognostic value of SGUS in a cohort of 70 patients with
pSS. These patients were selected from a cohort of 84 patients, and one criterion for exclusion
was biologic or immunosuppressive therapy in the past 3 months. Most patients used hydroxy-
chloroquine, omega 3, eye drops, and artificial saliva. We found an association of more severe
SGUS scores (3 and 4) with the presence of anti-Ro/SSA antibodies, IgG levels> 1600 mg/dL,
and an ESSDAI5, which is consistent with the findings in the literature [15, 16]. There was no
association with longer disease duration although a positive relationship was found between dis-
ease severity and low salivary flow. Although the new 2016 criteria withdrew the anti-La/SSB
antibody from use due to its low specificity, in the present study, we observed that the anti-Ro/
SSA group had higher SGUS scores than the anti-La/SSB group.
Since the study published in 1992 by De Vita et al. [13], SGUS has emerged as a promising
tool for the diagnosis and prognostic stratification of patients with primary or secondary
Table 1. Cohort characteristics.
Variables Groups
Score 1 or 2 (n = 23) Score 3 or 4 (n = 47) p-value
Age (years), mean (SD) 57.3 (10.9) 55.0 (12.4) 0.434*
Sex M:F, n (%) 1 (4.3): 22 (95.7) 1 (2.1): 46 (97.9) 0.600**
Disease duration (years), mean (95%CI) 9.3 (6.5–12.2) 6.9 (5.2–8.5) 0.101*
ESSDAI, mean (95%CI) 1.65 (0.81–2.49) 3.89 (2.77–5.01) 0.013***
Categorical ESSDAI, n (%) 0.064**
ESSDAI < 5 20 (87.0) 31 (66.0)
ESSDAI 5 3 (13.0) 16 (34.0)
Salivary flow, mean (95%CI) 0.23 (0.14–0.32) 0.10 (0.07–0.13) 0.001***
ANA, n (%) 0.006**
Positive 15 (65.2) 43 (91.5)
Negative 8 (34.8) 4 (8.5)
Anti-Ro/SSA, n (%) 0.003**
Positive 7 (30.4) 32 (68.1)
Negative 16 (69.6) 15 (31.9)
Anti-La/SSB, n (%) 0.077**
Positive 4 (17.4) 18 (38.3)
Negative 19 (82.6) 29 (61.7)
RF, n (%) 0.034**
Positive 8 (34.8) 29 (61.7)
Negative 15 (65.2) 18 (38.3)
IgG, mean (95%CI) 1268.9 (1083.8–1454.0) 1543.6 (1363.5–1723.6) 0.281*
Categorical IgG, n (%) 0.077**
 1600 mg/dL 19 (82.6) 29 (61.7)
> 1600 mg/dL 4 (17.4) 18 (38.3)
Salivary β2M, mean (95%CI) 3.18 (2.00–4.37) 3.98 (2.19–5.77) 0.547***
Serum β2M, mean (95%CI) 2.27 (0.95–3.59) 5.73 (2.56–8.89) 0.088***
ANA, antinuclear antibodies; β2M, beta-2 microglobulin; ESSDAI, European League Against Rheumatism (EULAR) Sjo¨gren’s syndrome disease activity
index; IgG, immunoglobulin G; RF, rheumatoid factor.
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Sjo¨gren’s syndrome. Some studies have reported that, although SGUS would be highly specific
for the diagnosis of the disease, this is not sufficient to make it part of the diagnostic criteria
[20]. However, SGUS is a feasible and inexpensive method that has proven useful for assessing
major salivary gland involvement in Sjo¨gren’s syndrome, exhibiting good diagnostic proper-
ties [8, 10, 12, 21]. The present findings confirm what has been reported in the literature.
In 2013, Cornec et al. [12] performed SGUS in a prospective cohort of patients with sus-
pected pSS. SGUS was able to distinguish patients with pSS (n = 78) from controls (n = 80)
with 62.8% sensitivity, 95.0% specificity, 92.5% positive predictive value, and 72.4% negative
predictive value. We used the Cornec classification in the present study, which establishes four
scores according to inhomogeneity and size of the anechoic area.
The relationship between SGUS scores and disease severity has been demonstrated in
recent studies [11, 15, 16]. Hammenfors et al. [16] investigating 97 patients showed that those
with severe changes determined by SGUS tended to be younger and had a higher degree of
subjective and objective findings, indicating a patient subgroup with more severe pSS. The
authors also found that increased dry mouth, fatigue and serological alterations were associ-
ated with more severe parenchymal findings on SGUS.
Niemela¨ et al. [11] found a strong correlation between the concentrations of ANA and anti-
Ro/SSA and/or anti-La/SSB antibodies in 97% of patients with parenchymal heterogeneity of
the salivary glands visible on SGUS. Theander and Mandl [15] recruited 105 patients with pSS
and, using a simplified SGUS scoring system, showed that patients with a more severe SGUS
score had a higher frequency of autoantibodies (anti-Ro/SSA and anti-La/SSB, ANA, and
rheumatoid factor) and significantly higher levels of IgG than patients with normal SGUS find-
ings. More interestingly, they found that disease activity, as measured by the ESSDAI, was sig-
nificantly higher in these patients and there was a significant association between SGUS scores
and lymphoma risk factors, including germinal center-like structures in the minor salivary
gland, CD4+ T cell lymphopenia, reduced number of memory B cells in the circulation, mono-
clonal immunoglobulin in serum, presence of salivary gland swelling, purpura, and skin
vasculitis.
SGUS may thus serve as a useful tool in selecting subgroups of patients who require closer
follow-up. However, whether the time elapsed between the onset of symptoms and diagnosis is
an important factor remains to be clarified. Future studies should therefore investigate serum
biomarkers [22] in combination with noninvasive methods, such as SGUS, about their useful-
ness in the early detection of patients with pSS.
ESSDAI for pSS is a tool that helps clinicians evaluate disease activity [17]. The ESSDAI
grades 12 organ-specific domains on a scale of severity of involvement, ranging from 0 (no
activity) to 3 (high activity). These scores are then multiplied by an assigned weight factor,
ranging from 1 to 6. Total scores range from 0 to 123. Most patients in studies using the ESS-
DAI as an outcome have shown a mean total score of 13 [23]. In our cohort, a mean (SD) ESS-
DAI of 3.15 (3.47) was observed, indicating a group with mild disease.
De Vita et al. [24], in a study on belimumab for pSS, reported a mean (SD) ESSDAI of 8.8
(7.4) at baseline. In the study by Kedor et al. [25], the mean (SD) ESSDAI at baseline was 5.5
(3.3). In a validation study conducted in Argentina, a mean ESSDAI of 5 was observed (rang-
ing from 3 to 9), indicating the prevalence of patients with low disease activity or inactivity
[26]. Studies conducted in different countries where the ESSDAI is applied have shown mean
values of 4 (0 to 43) in an English cohort, 5.7 (0 to 29) in a French cohort, 3.18 (0 to 29) in a
Dutch cohort, and 11.1 (0 to 37) in a Finnish cohort [23, 26–29]. In all these samples, the values
indicate patients with low disease activity. In a study involving 62 patients with pSS for the
transcultural adaptation of the ESSDAI into Brazilian Portuguese, the authors found a mean
(SD) ESSDAI of 4.95 (6.73) [30]. In the present study, the ESSDAI was able to distinguish two
Salivary gland ultrasonography importance for Sjo¨gren’s syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0182287 August 4, 2017 6 / 10
groups of patients: 23 patients with a mean ESSDAI of 1.65 (95%CI 0.81–2.49) and 47 patients
with a mean ESSDAI of 3.89 (95%CI 2.77–5.01).
Studies have reported that high serum β2M levels reflect clinical activity, systemic activity,
and high lymphoma risk [29]. Salivary β2M levels, in turn, have been related to pSS in some
studies as a biomarker for diagnostic purposes [31–33]. Thus, measurement of β2M levels in
inflammatory fluids may provide a simple method for quantifying local activity in autoim-
mune states [34]. Elevated β2M concentrations were found in the saliva of patients with pSS
and in the synovial fluid of patients with rheumatoid arthritis [34]. In addition, a correlation
was found between elevated salivary β2M concentration and the degree of inflammation seen
in the labial salivary gland biopsy [35].
In the present study, β2M levels were measured in serum and saliva in order to evaluate
whether this biomarker would be able to detect disease severity in accordance with a high
activity index, low salivary flow, and high SGUS score. However, our results were not consis-
tent with a high ESSDAI, high SGUS score, or low salivary flow. A possible explanation for this
may be the small sample size and absence of gland inflammatory reaction due to long disease
duration. It is therefore a tempting prospect to test β2M levels in the early stages of the disease
when there are no inflammatory changes in glandular tissue function.
Because our patients had a very low salivary secretion, stimulated saliva collection was
required to obtain optimal amounts of saliva samples for β2M measurements. Some studies
have demonstrated the reliability of stimulated salivary flow, providing a good application
method [36]. Stimulated whole salivary flow correlated better with minor salivary gland
pathology than with unstimulated salivary flow and may therefore serve as a noninvasive sur-
rogate biomarker of inflammation and fibrosis as well as a measure of response to treatment in
patients with pSS [37]. In the present study, citric acid was used on both sides of the tongue,
three drops on each side, and collection began after the citric acid had been swallowed. Never-
theless, a better standardization of the collection and processing of saliva as well as further vali-
dation, refinement, and technical improvements will be required in studies aiming to identify
salivary biomarkers [37].
Polyclonal hypergammaglobulinemia is one of the most characteristic laboratory abnormal-
ities found in pSS. It reflects the polyclonal B-cell activation implicated in the pathogenesis of
the disease and provides useful analytical data that may strengthen the diagnosis of pSS in
patients with sicca syndrome [38]. Hypergammaglobulinemia is closely associated with the
key immunological markers of Sjo¨gren’s syndrome (rheumatoid factor, anti-Ro/SSA, and anti-
La/SSB). Several studies have reported that up to 10% of patients with pSS may have associated
monoclonal gammopathy of undetermined significance (MGUS). This gammopathy was
included as a key marker of disease activity in the proposed ESSDAI [17]. In our cohort, 31.5%
of patients with a more severe SGUS score had IgG levels > 1600 mg/dL.
This study has some limitations that should be taken into account when interpreting the
results. The SGUS was performed by a single examiner who, despite having sufficient expertise
in the examination, was not blinded to the diagnosis. However, the examiner was asked to
assign only the score of severity of salivary gland involvement, according to the Cornec classifi-
cation, and was blinded to all other disease or patient data. A labial salivary gland biopsy could
have added more data to the evaluation of prognosis. Only 20% of our patients had labial sali-
vary gland biopsies. In our department, a biopsy is performed only if the 2002 AECG criteria
are not fulfilled.
In summary, our sample consisted of patients with pSS already diagnosed in the commu-
nity hospital setting who were referred to our institution through different specialties related
to the disease (dentists, ophthalmologists, rheumatologists, and otolaryngologists). This fact
encourages us to believe that our results reflect a real-world scenario. In addition, some
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associations found in the present study could improve patient follow-up, such as patients with
high SGUS scores need to be followed more closely as they are at increased risk of poor prog-
nosis. It is also important to promote the application of the ESSDAI in clinical situations, since
this index could measure the likelihood of poor outcomes more accurately.
Finally, it is recommended that further research be conducted in a large population, using
SGUS as a tool to measure disease severity, for a prolonged observation time to determine
other aspects of systemic manifestations that match additional characteristics of severity mea-
sured with the ESSDAI. We believe that SGUS is an affordable, convenient and reliable option
to detect Sjo¨gren’s syndrome, with the advantage of avoiding unnecessary radiation exposure
as in sialography and scintigraphy.
Conclusion
The associations observed in the present study between SGUS, severity of dryness symptoms,
exocrine gland function, systemic autoantibodies, and disease activity indicate the usefulness
of SGUS as a tool to assess salivary gland involvement in pSS. Further studies are needed to
elucidate the potential role of major salivary gland ultrasound imaging as a diagnostic and
prognostic tool in pSS.
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